Guillain-Barré Syndrome: A Global Perspective on Management, Diagnosis, and Future Challenges

References

1. Afifi A. The landry-guillain-barre strohl syndrome 1859 to 1992 A Historical Perspective. J. Family Community Med. 1994 1 1 30 34 10.4103/2230‑8229.98709 23008532
   [Google Scholar]
2. Rzepiński Ł. Grzybowski A. Guillain-Barré or Guillain-Barré-Strohl syndrome: Medical and non-medical reasons for omitting Andre Strohl from the eponym. Arch. Med. Sci. 2022 18 4 1127 1129 10.5114/aoms/150713 35832694
   [Google Scholar]
3. Jasem J. Marof K. Nawar A. Guillain-Barré syndrome as a cause of acute flaccid paralysis in Iraqi children: A result of 15 years of nation-wide study. BMC Neurol. 2013 13 1 195 10.1186/1471‑2377‑13‑195 24325332
   [Google Scholar]
4. Kong L. Wang J. Wu X. Distribution characteristics of antinuclear antibodies in Guillain-Barré syndrome and its relationship with disease severity. Clin. Neurol. Neurosurg. 2024 244 108421 10.1016/j.clineuro.2024.108421 38971125
   [Google Scholar]
5. Papri N. Islam Z. Leonhard S.E. Mohammad Q.D. Endtz H.P. Jacobs B.C. Guillain–Barré syndrome in low-income and middle-income countries: Challenges and prospects. Nat. Rev. Neurol. 2021 17 5 285 296 10.1038/s41582‑021‑00467‑y 33649531
   [Google Scholar]
6. Nachamkin I. Allos B.M. Ho T. Campylobacter species and Guillain-Barré syndrome. Clin. Microbiol. Rev. 1998 11 3 555 567 10.1128/CMR.11.3.555 9665983
   [Google Scholar]
7. Nejad J.H. Heiat M. Hosseini M.J. Guillain-Barré syndrome associated with COVID-19: A case report study. J. Neurovirol. 2021 27 5 802 805 10.1007/s13365‑021‑00984‑y 34046865
   [Google Scholar]
8. Abuawwad M.T. Taha M.J.J. Taha A.J. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports. Clin. Neurol. Neurosurg. 2024 238 108183 10.1016/j.clineuro.2024.108183 38401232
   [Google Scholar]
9. Bragazzi N.L. Kolahi A.A. Nejadghaderi S.A. Global, regional, and national burden of Guillain–Barré syndrome and its underlying causes from 1990 to 2019. J. Neuroinflammation 2021 18 1 264 10.1186/s12974‑021‑02319‑4 34763713
   [Google Scholar]
10. Ishaque T. Islam M.B. Ara G. High mortality from Guillain‐Barré syndrome in Bangladesh. J. Peripher. Nerv. Syst. 2017 22 2 121 126 10.1111/jns.12215 28447405
    [Google Scholar]
11. Madden J. Spadaro A. Koyfman A. Long B. High risk and low prevalence diseases: Guillain-Barré syndrome. Am. J. Emerg. Med. 2024 75 90 97 10.1016/j.ajem.2023.10.036 37925758
    [Google Scholar]
12. Wachira V.K. Farinasso C.M. Silva R.B. Peixoto H.M. de Oliveira M.R.F. Incidence of Guillain-Barré syndrome in the world between 1985 and 2020: A systematic review. Glob. Epidemiol. 2023 5 100098 10.1016/j.gloepi.2023.100098 37638372
    [Google Scholar]
13. Shahrizaila N. Lehmann H.C. Kuwabara S. Guillain-Barré syndrome. Lancet 2021 397 10280 1214 1228 10.1016/S0140‑6736(21)00517‑1 33647239
    [Google Scholar]
14. Laman J.D. Huizinga R. Boons G.J. Jacobs B.C. Guillain-Barré syndrome: Expanding the concept of molecular mimicry. Trends Immunol. 2022 43 4 296 308 10.1016/j.it.2022.02.003 35256276
    [Google Scholar]
15. van den Berg B. Walgaard C. Drenthen J. Fokke C. Jacobs B.C. van Doorn P.A. Guillain–Barré syndrome Pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 2014 10 8 469 482 10.1038/nrneurol.2014.121 25023340
    [Google Scholar]
16. Willison H.J. Jacobs B.C. van Doorn P.A. Guillain-Barré syndrome. Lancet 2016 388 10045 717 727 10.1016/S0140‑6736(16)00339‑1 26948435
    [Google Scholar]
17. Berciano J. Microscopical anatomy of the peripheral nervous system: An essential notion for understanding the pathophysiology of very early classic Guillain-Barré syndrome. Neuropathology 2024 45 2 85 99 10.1111/neup.13006 39350534
    [Google Scholar]
18. van Doorn P.A. Chapter 2 Guillain-Barré syndrome In: Dysimmune Neuropathies. Chapter 2 Academic Press 2020 5 29 10.1016/B978‑0‑12‑814572‑2.00002‑9
    [Google Scholar]
19. Hughes R.A.C. Guillain‐Barré syndrome: History, pathogenesis, treatment, and future directions. Eur. J. Neurol. 2024 31 11 e16346 10.1111/ene.16346 38752584
    [Google Scholar]
20. Wang Y. Sun S. Zhu J. Cui L. Zhang H.L. Biomarkers of Guillain‐Barré syndrome: Some recent progress, more still to be explored. Mediators Inflamm. 2015 2015 1 564098 10.1155/2015/564098 26451079
    [Google Scholar]
21. Hafsteinsdóttir B. Farman H. Lagerström N. Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain–Barré syndrome. J. Neurol. 2024 271 11 7282 7293 10.1007/s00415‑024‑12679‑5 39249104
    [Google Scholar]
22. Berciano J. Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: A pathophysiological annotation. Brain 2024 147 1 e1 e2 10.1093/brain/awad277 37587331
    [Google Scholar]
23. Hughes R.A.C. Swan A.V. Raphaël J.C. Annane D. van Koningsveld R. van Doorn P.A. Immunotherapy for Guillain-Barre syndrome: A systematic review. Brain 2007 130 9 2245 2257 10.1093/brain/awm004 17337484
    [Google Scholar]
24. Khan S.A. Das P.R. Nahar Z. Dewan S.M.R. An updated review on Guillain-Barré syndrome: Challenges in infection prevention and control in low- and middle-income countries. SAGE Open Med. 2024 12 20503121241239538 10.1177/20503121241239538 38533198
    [Google Scholar]
25. Rajabally Y.A. Immunoglobulin and monoclonal antibody therapies in guillain-barré syndrome. Neurotherapeutics 2022 19 3 885 896 10.1007/s13311‑022‑01253‑4 35648286
    [Google Scholar]
26. van der Meché F.G.A. van Doorn P.A. Guillain-barré syndrome. Curr. Treat. Options Neurol. 2000 2 6 507 516 10.1007/s11940‑000‑0029‑7 11096775
    [Google Scholar]
27. Verboon C. Harbo T. Cornblath D.R. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: An international observational study. J. Neurol. Neurosurg. Psychiatry 2021 92 10 1080 1088 10.1136/jnnp‑2020‑325815 34103340
    [Google Scholar]
28. Nayeem A. Mohammad Q.D. Susan Z.S. A systematic review on immunotherapy for Guillain-Barre syndrome. J. Bangladesh Coll. Phys. Surg. 2022 40 1 57 64 10.3329/jbcps.v40i1.57060
    [Google Scholar]
29. Meena A.K. Khadilkar S.V. Murthy J.M.K. Treatment guidelines for Guillain-Barré syndrome. Ann. Indian Acad. Neurol. 2011 14 Suppl. 1 73 10.4103/0972‑2327.83087 21847334
    [Google Scholar]
30. Leonhard S.E. Mandarakas M.R. Gondim F.A.A. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat. Rev. Neurol. 2019 15 11 671 683 10.1038/s41582‑019‑0250‑9 31541214
    [Google Scholar]
31. Nagpal S. Benstead T. Shumak K. Rock G. Brown M. Anderson D.R. Treatment of Guillain-Barré syndrome: A cost-effectiveness analysis. J. Clin. Apher. 1999 14 3 107 113 10.1002/(SICI)1098‑1101(1999)14:3<107:AID‑JCA1>3.0.CO;2‑3 10540364
    [Google Scholar]
32. Yao J. Zhou R. Liu Y. Lu Z. Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years. Hum. Vaccin. Immunother. 2023 19 2 2215153 10.1080/21645515.2023.2215153 37278272
    [Google Scholar]
33. Baranwal A.K. Ravi R.N.M. Singh R. Exchange transfusion: A low-cost alternative for severe childhood Guillain-Barré syndrome. J. Child Neurol. 2006 21 11 960 965 10.1177/08830738060210111201 17092462
    [Google Scholar]
34. Bayu H.T. Demilie A.E. Molla M.T. Kumie F.T. Endeshaw A.S. Mortality and its predictors among patients with Guillain–Barré syndrome in the intensive care unit of a low-income country, Ethiopia: A multicenter retrospective cohort study. Front. Neurol. 2024 15 1484661 10.3389/fneur.2024.1484661 39559822
    [Google Scholar]